Cingulate Receives Complete Response Letter from FDA for ADHD Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: NASDAQ.COM
- FDA Response Letter: Cingulate Inc. has received a Complete Response Letter from the FDA regarding its New Drug Application for CTx-1301, aimed at treating ADHD, which identified specific requests related to Chemistry, Manufacturing, and Controls (CMC) but raised no concerns about the clinical safety or efficacy of the drug.
- Clear Priorities: CEO Shane J. Schaffer emphasized that the immediate priority is to complete the ongoing CMC work with their manufacturing partner, with expectations to quickly address the outstanding requests and efficiently move towards resubmission.
- Strong Financial Position: The company holds nearly $30 million in cash reserves, which is deemed sufficient to tackle the issues raised by the FDA and to execute the resubmission process while continuing pre-commercial activities into 2027, ensuring competitive positioning in the market.
- Positive Stock Reaction: Following a closing price of $3.60 on Monday, Cingulate's shares rose over 5% in pre-market trading, reflecting market optimism regarding the company's future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CING?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CING
Wall Street analysts forecast CING stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.120
Low
8.00
Averages
27.33
High
58.00
Current: 5.120
Low
8.00
Averages
27.33
High
58.00
About CING
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Cingulate Receives Complete Response Letter from FDA for ADHD Drug
- FDA Response Letter: Cingulate Inc. has received a Complete Response Letter from the FDA regarding its New Drug Application for CTx-1301, aimed at treating ADHD, which identified specific requests related to Chemistry, Manufacturing, and Controls (CMC) but raised no concerns about the clinical safety or efficacy of the drug.
- Clear Priorities: CEO Shane J. Schaffer emphasized that the immediate priority is to complete the ongoing CMC work with their manufacturing partner, with expectations to quickly address the outstanding requests and efficiently move towards resubmission.
- Strong Financial Position: The company holds nearly $30 million in cash reserves, which is deemed sufficient to tackle the issues raised by the FDA and to execute the resubmission process while continuing pre-commercial activities into 2027, ensuring competitive positioning in the market.
- Positive Stock Reaction: Following a closing price of $3.60 on Monday, Cingulate's shares rose over 5% in pre-market trading, reflecting market optimism regarding the company's future developments.
See More
Cingulate Receives FDA Response, Plans Prompt Information Submission
- FDA Response Details: Cingulate Inc. received a Complete Response Letter from the FDA, primarily focused on Chemistry, Manufacturing, and Controls (CMC) information requests, without raising concerns regarding the clinical safety or efficacy of CTx-1301, which signals a positive outlook for the company's drug application.
- Strong Financial Position: The company is well-capitalized with nearly $30 million in cash reserves, which is sufficient to address the FDA's requests and execute the resubmission process while continuing pre-commercial activities into 2027, ensuring ongoing business momentum.
- Significant Market Potential: The U.S. ADHD market has approximately 100 million annual prescriptions, with over 20 million diagnosed patients, including 12 million adults, indicating a rapidly growing demand for adult ADHD treatments, positioning Cingulate's products favorably in this expanding market.
- Technological Platform Advantage: CTx-1301 utilizes Cingulate's Precision Timed Release (PTR) platform designed to provide rapid onset and all-day efficacy, with the company's innovative technology poised to significantly improve treatment outcomes in ADHD, enhancing patient medication experiences.
See More
Cingulate Reports Increased Q1 Net Loss Amid Cash Growth
- Net Loss Overview: Cingulate reported a net loss of $9.3 million for Q1 2026, a significant increase from the $3.9 million loss in Q1 2025, indicating financial pressures during its expansion phase.
- Liquidity Improvement: As of March 31, 2026, Cingulate had approximately $25.9 million in cash and cash equivalents, reflecting a $14.9 million increase from December 31, 2025, primarily driven by a $12.0 million private placement completed in Q1.
- Working Capital Growth: The company's working capital rose to approximately $17.0 million as of March 31, 2026, a substantial increase of $15.3 million compared to $1.7 million as of December 31, 2025, showcasing improved financial management.
- Funding Context Analysis: The successful fundraising not only bolstered the company's liquidity but also provided essential funding for future business expansion and R&D, although the ongoing losses still need to be addressed in the short term.
See More
Cingulate Reports Slight Increase in Q4 Net Loss
- Financial Performance: Cingulate reported a net loss of $6.3 million for Q4 2025, slightly up from $6.2 million in Q4 2024, indicating ongoing challenges in achieving profitability.
- Cash Flow Status: As of December 31, 2025, Cingulate had approximately $11.0 million in cash and cash equivalents, a decrease of $1.3 million from the previous year, reflecting pressure on the company's liquidity management.
- Working Capital Changes: The reduction in working capital may impact the company's future investment capabilities and operational flexibility, particularly in research and development and marketing efforts.
- Market Reaction: Despite the lack of significant improvement in financial data, investors remain cautiously optimistic about Cingulate's long-term potential, which may influence its stock price performance.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Cingulate Receives Complete Response Letter from FDA for ADHD Drug
- FDA Response Letter: Cingulate Inc. has received a Complete Response Letter from the FDA regarding its New Drug Application for CTx-1301, aimed at treating ADHD, which identified specific requests related to Chemistry, Manufacturing, and Controls (CMC) but raised no concerns about the clinical safety or efficacy of the drug.
- Clear Priorities: CEO Shane J. Schaffer emphasized that the immediate priority is to complete the ongoing CMC work with their manufacturing partner, with expectations to quickly address the outstanding requests and efficiently move towards resubmission.
- Strong Financial Position: The company holds nearly $30 million in cash reserves, which is deemed sufficient to tackle the issues raised by the FDA and to execute the resubmission process while continuing pre-commercial activities into 2027, ensuring competitive positioning in the market.
- Positive Stock Reaction: Following a closing price of $3.60 on Monday, Cingulate's shares rose over 5% in pre-market trading, reflecting market optimism regarding the company's future developments.
See More
Cingulate Receives FDA Response, Plans Prompt Information Submission
- FDA Response Details: Cingulate Inc. received a Complete Response Letter from the FDA, primarily focused on Chemistry, Manufacturing, and Controls (CMC) information requests, without raising concerns regarding the clinical safety or efficacy of CTx-1301, which signals a positive outlook for the company's drug application.
- Strong Financial Position: The company is well-capitalized with nearly $30 million in cash reserves, which is sufficient to address the FDA's requests and execute the resubmission process while continuing pre-commercial activities into 2027, ensuring ongoing business momentum.
- Significant Market Potential: The U.S. ADHD market has approximately 100 million annual prescriptions, with over 20 million diagnosed patients, including 12 million adults, indicating a rapidly growing demand for adult ADHD treatments, positioning Cingulate's products favorably in this expanding market.
- Technological Platform Advantage: CTx-1301 utilizes Cingulate's Precision Timed Release (PTR) platform designed to provide rapid onset and all-day efficacy, with the company's innovative technology poised to significantly improve treatment outcomes in ADHD, enhancing patient medication experiences.
See More
Cingulate Reports Increased Q1 Net Loss Amid Cash Growth
- Net Loss Overview: Cingulate reported a net loss of $9.3 million for Q1 2026, a significant increase from the $3.9 million loss in Q1 2025, indicating financial pressures during its expansion phase.
- Liquidity Improvement: As of March 31, 2026, Cingulate had approximately $25.9 million in cash and cash equivalents, reflecting a $14.9 million increase from December 31, 2025, primarily driven by a $12.0 million private placement completed in Q1.
- Working Capital Growth: The company's working capital rose to approximately $17.0 million as of March 31, 2026, a substantial increase of $15.3 million compared to $1.7 million as of December 31, 2025, showcasing improved financial management.
- Funding Context Analysis: The successful fundraising not only bolstered the company's liquidity but also provided essential funding for future business expansion and R&D, although the ongoing losses still need to be addressed in the short term.
See More
Cingulate Reports Slight Increase in Q4 Net Loss
- Financial Performance: Cingulate reported a net loss of $6.3 million for Q4 2025, slightly up from $6.2 million in Q4 2024, indicating ongoing challenges in achieving profitability.
- Cash Flow Status: As of December 31, 2025, Cingulate had approximately $11.0 million in cash and cash equivalents, a decrease of $1.3 million from the previous year, reflecting pressure on the company's liquidity management.
- Working Capital Changes: The reduction in working capital may impact the company's future investment capabilities and operational flexibility, particularly in research and development and marketing efforts.
- Market Reaction: Despite the lack of significant improvement in financial data, investors remain cautiously optimistic about Cingulate's long-term potential, which may influence its stock price performance.
See More
